AP1M2

Across TCGA pan-cancer cohorts, AP1M2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AP1M2 data layer compared with 16 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AP1M2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AP1M2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and UCEC are the cancer types where AP1M2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.413	0.185	<.001	64	view →
COAD	DFS	Median	II,III,IV	1.000	0.881	.020	30	view →
UCEC	OS	Tertile	All	1.000	0.901	.017	12	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	7	view →
LUAD	DFS	Tertile	All	0.495	0.845	.002	6	view →
CCRCC	DFS	Quartile	III,IV	0.815	0.550	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AP1M2–PDAC (DFS)

Open the PDAC breakdown →